A Medicare pipeline

Selected biotech compounds in Phase III or under FDA review that could be affected by the proposed Medicare prescription drug benefit. Although the Biotechnology Industry Organization estimates that 350 biotech drug candidates and vaccines are in clinical development, the benefit would not apply to compounds administered in hospitals or physicians' offices, which are already covered by Medicare.

Complete name Product name Indication Status
Algos (ALGO) HydrocoDex oral tablet Moderate to severe pain III
Algos (ALGO) MorphiDex oral tablet Moderate to severe pain NDA